

Health Advisory: REGEN-COV Approved for Post-Exposure Prophylactic Use

Minnesota Department of Health, Mon, Aug 2 13:00 CDT 2021

Action Steps

Local and tribal health department: Please forward to hospitals, clinics, emergency departments, urgent care centers, and convenience clinics in your jurisdiction.

Hospitals, clinics and other facilities: Please forward to infection preventionists, infectious disease physicians, emergency department staff, hospitalists, primary care clinicians, and all other health care providers who might see patients with COVID-19.

Health care providers:

- Consider providing REGEN-COV monoclonal antibody therapy for post-exposure prophylaxis (PEP) to persons not fully vaccinated for COVID-19 or persons not expected to mount an adequate immune response to SARS-CoV-2 vaccination AND
 - have been exposed to an individual infected with SARS-CoV-2 consistent with close contact criteria per CDC OR
 - who are at high risk of exposure to an individual infected with SARS-CoV-2 because of occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting (for example, congregate care settings like long-term care or prisons)
- Offer subcutaneous injection if infusion is not feasible or would significantly delay treatment.
- Find out which monoclonal therapies are applicable to your patient and where they can get those therapies at [Minnesota Resource Allocation Platform for COVID-19 Treatment](https://www.health.state.mn.us/diseases/coronavirus/mnrap.html) <https://www.health.state.mn.us/diseases/coronavirus/mnrap.html>
- Call the MDH COVID-19 Provider Hotline at 651-201-5414 or 877-676-5414, option 3 for more information.

Summary

On July 30, 2021, the Food and Drug Administration (FDA) authorized an additional use for the COVID-19 monoclonal antibody therapy REGEN-COV (casirivimab and imdevimab). The REGEN-COV Emergency Use Authorization (EUA) has been expanded to include post-exposure prophylaxis. This new authorization is in addition to the prior authorization of REGEN-COV to treat non-hospitalized patients with mild to moderate COVID-19 in adult and pediatric patients, age 12 and older, with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

REGEN-COV is expected to be effective against circulating variants, including the Delta variant. **It should be noted that post-exposure prophylaxis with REGEN-COV is not a substitute for vaccination against COVID-19 and REGEN-COV is not authorized for pre-exposure prophylaxis.**

HEALTH ADVISORY: REGEN-COV APPROVED FOR POST-EXPOSURE PROPHYLACTIC USE

For both non-hospitalized treatment and post-exposure prophylaxis use, the authorized dose is 600 mg of casirivimab and 600 mg of imdevimab. For treatment of mild to moderate COVID-19, a single intravenous infusion is strongly recommended; however, subcutaneous injection may be an alternative if infusion is not feasible or would significantly delay treatment. For post-exposure prophylaxis, REGEN-COV may be administered as either subcutaneous injection or a single IV infusion. Please refer to the following links for full details about dosing and administration.

- HHS/ASPR: REGEN-COV Authorized by FDA for Post-Exposure Prophylaxis under Emergency Use Authorization
https://www.phe.gov/emergency/events/COVID19/investigation-MCM/cas_imd/Pages/update-30July2021.aspx
- [FDA: Fact Sheet for Health Care Providers Emergency Use Authorization \(EUA\) of REGEN-COV \(casirivimab and imdevimab\)](https://www.fda.gov/media/145611/download)
<https://www.fda.gov/media/145611/download>
- [MDH Therapeutic Options for COVID-19 Patients:](https://www.health.state.mn.us/diseases/coronavirus/hcp/therapeutic.html)
<https://www.health.state.mn.us/diseases/coronavirus/hcp/therapeutic.html>
- [MDH COVID-19 Medication Options:](https://www.health.state.mn.us/diseases/coronavirus/meds.html)
<https://www.health.state.mn.us/diseases/coronavirus/meds.html>

Higher Risk Patients

- [CDC People with Certain Medical Conditions](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html) <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html>
- [CDC Underlying Medical Conditions Associated with High Risk for Severe COVID-19: Information for Healthcare Providers](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html) <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html>

For More Information

- [FDA Drug and Biological Therapeutic Products](https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs) <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs>
- [FDA Combating COVID-19 with Therapeutics \(PDF\)](https://www.fda.gov/media/136832/download)
<https://www.fda.gov/media/136832/download>

A copy of this HAN is available at: [MDH Health Alert Network](http://www.health.state.mn.us/han)
(<http://www.health.state.mn.us/han>)

The content of this message is intended for public health and health care personnel and response partners who have a need to know the information to perform their duties.